Literature DB >> 22922976

Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists.

Yong-Chul Kim1, Emidio Camaioni, Airat U Ziganshin, Xiao-Duo Ji, Brian F King, Scott S Wildman, Alexei Rychkov, Joshua Yoburn, Heaok Kim, Arvind Mohanram, T Kendall Harden, José L Boyer, Geoffrey Burnstock, Kenneth A Jacobson.   

Abstract

Novel analogs of the P2 receptor antagonist pyridoxal-5'-phosphate-6-phenylazo-2',4'-disulfonate (PPADS) were synthesized. Modifications were made through functional group substitution on the sulfophenyl ring and at the phosphate moiety through the inclusion of phosphonates, demonstrating that a phosphate linkage is not required for P2 receptor antagonism. Substituted 6-phenylazo and 6-naphthylazo derivatives were also evaluated. Among the 6-phenylazo derivatives, 5'-methyl, ethyl, propyl, vinyl, and allyl phosphonates were included. The compounds were tested as antagonists at turkey erythrocyte and guinea-pig taenia coli P2Y(1) receptors, in guinea-pig vas deferens and bladder P2X(1) receptors, and in ion flux experiments by using recombinant rat P2X(2) receptors expressed in Xenopus oocytes. Competitive binding assay at human P2X(1) receptors in differentiated HL-60 cell membranes was carried out by using [(35)S]ATP-γ-S. A 2'-chloro-5'-sulfo analog of PPADS (C(14)H(12)O(9)N(3)ClPSNa), a vinyl phosphonate derivative (C(15)H(12)O(11)N(3)PS(2)Na(3)), and a naphthylazo derivative (C(18)H(14)O(12)N(3)PS(2)Na(2)), were particularly potent in binding to human P2X(1) receptors. The potencies of phosphate derivatives at P2Y(1) receptors were generally similar to PPADS itself, except for the p-carboxyphenylazo phosphate derivative C(15)H(13)O(8)N(3)PNa and its m-chloro analog C(15)H(12)O(8)N(3)ClPNa, which were selective for P2X vs. P2Y(1) receptors. C(15)H(12)O(8)N(3)ClPNa was very potent at rat P2X(2) receptors with an IC(50) value of 0.82 μM. Among the phosphonate derivatives, [4-formyl-3-hydroxy-2-methyl-6-(2-chloro-5-sulfonylphenylazo)-pyrid-5-yl]methylphosphonic acid (C(14)H(12)-O(8)N(3)ClPSNa) showed high potency at P2Y(1) receptors with an IC(50) of 7.23 μM. The corresponding 2,5-disulfonylphenyl derivative was nearly inactive at turkey erythrocyte P2Y(1) receptors, whereas at recombinant P2X(2) receptors had an IC(50) value of 1.1 μM. An ethyl phosphonate derivative (C(15)H(15)O(11)N(3)PS(2)Na(3)), whereas inactive at turkey erythrocyte P2Y(1) receptors, was particularly potent at recombinant P2X(2) receptors.

Entities:  

Year:  1998        PMID: 22922976      PMCID: PMC3424000          DOI: 10.1002/(SICI)1098-2299(199810)45:2<52::AID-DDR2>3.0.CO;2-V

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  37 in total

Review 1.  P2 purinoceptors: historical perspective and classification.

Authors:  G Burnstock
Journal:  Ciba Found Symp       Date:  1996

Review 2.  Challenges in developing P2 purinoceptor-based therapeutics.

Authors:  M Williams
Journal:  Ciba Found Symp       Date:  1996

3.  Towards a revised nomenclature for P1 and P2 receptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; G R Dubyak; T K Harden; K A Jacobson; U Schwabe; M Williams
Journal:  Trends Pharmacol Sci       Date:  1997-03       Impact factor: 14.819

4.  Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors.

Authors:  E Camaioni; J L Boyer; A Mohanram; T K Harden; K A Jacobson
Journal:  J Med Chem       Date:  1998-01-15       Impact factor: 7.446

5.  Phosphoinositide hydrolysis by guanosine 5'-[gamma-thio]triphosphate-activated phospholipase C of turkey erythrocyte membranes.

Authors:  T K Harden; P T Hawkins; L Stephens; J L Boyer; C P Downes
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

6.  PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder.

Authors:  A U Ziganshin; C H Hoyle; X Bo; G Lambrecht; E Mutschler; H G Bäumert; G Burnstock
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Structure Activity Relationships for Derivatives of Adenosine-5'-Triphosphate as Agonists at P(2) Purinoceptors: Heterogeneity Within P(2X) and P(2Y) Subtypes.

Authors:  Geoffrey Burnstock; Bilha Fischer; Charles H V Hoyle; Michel Maillard; Airat U Ziganshin; Antonia L Brizzolara; Amy von Isakovics; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  2004-10-05       Impact factor: 4.360

8.  Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors.

Authors:  U Windscheif; V Ralevic; H G Bäumert; E Mutschler; G Lambrecht; G Burnstock
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens.

Authors:  G J McLaren; G Lambrecht; E Mutschler; H G Bäumert; P Sneddon; C Kennedy
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor.

Authors:  A J Brake; M J Wagenbach; D Julius
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

View more
  14 in total

Review 1.  Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis.

Authors:  K A Jacobson; C Hoffmann; Y C Kim; E Camaioni; E Nandanan; S Y Jang; D P Guo; X D Ji; I von Kügelgen; S Moro; A U Ziganshin; A Rychkov; B F King; S G Brown; S S Wildman; G Burnstock; J L Boyer; A Mohanram; T K Harden
Journal:  Prog Brain Res       Date:  1999       Impact factor: 2.453

2.  Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists.

Authors:  E Nandanan; E Camaioni; S Y Jang; Y C Kim; G Cristalli; P Herdewijn; J A Secrist; K N Tiwari; A Mohanram; T K Harden; J L Boyer; K A Jacobson
Journal:  J Med Chem       Date:  1999-05-06       Impact factor: 7.446

3.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

4.  EFFECT OF NEW PYRIDOXAL PHOSPHATE ARYLAZO DERIVATIVES ON THE ECTO-ATPase ACTIVITY IN GUINEA PIG TISSUES.

Authors:  A U Ziganshin; A P Zaitsev; I P Zaitseva; Yu Ch Kim; E Camaioni; G Burnstock; K A Jacobson
Journal:  Pharm Chem J       Date:  2000-05       Impact factor: 0.837

5.  Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.

Authors:  Jing Zhao; Yuhong Du; John R Horton; Anup K Upadhyay; Bin Lou; Yan Bai; Xing Zhang; Lupei Du; Minyong Li; Binghe Wang; Lixin Zhang; Joseph T Barbieri; Fadlo R Khuri; Xiaodong Cheng; Haian Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-09       Impact factor: 11.205

6.  Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors.

Authors:  Hung Chang; Ivan B Yanachkov; Alan D Michelson; YouFu Li; M R Barnard; George E Wright; Andrew L Frelinger
Journal:  Thromb Res       Date:  2009-11-27       Impact factor: 3.944

7.  Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds.

Authors:  Carsten Hoffmann; Petra Heine; Gabi Pradel; Yong-Chul Kim; Kenneth A Jacobson; Herbert Zimmermann
Journal:  Drug Dev Res       Date:  2001-01-24       Impact factor: 4.360

8.  Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors.

Authors:  Sean G Brown; Yong-Chul Kim; Soon-Ai Kim; Kenneth A Jacobson; Geoffrey Burnstock; Brian F King
Journal:  Drug Dev Res       Date:  2001-10-18       Impact factor: 4.360

9.  Evidence for the Recognition of Non-Nucleotide Antagonists Within the Transmembrane Domains of the Human P2Y(1) Receptor.

Authors:  Danping Guo; Ivar von Kügelgen; Stefano Moro; Yong-Chul Kim; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  2003-01-22       Impact factor: 4.360

Review 10.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.